CMAS

Across TCGA pan-cancer cohorts, CMAS mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CMAS data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CMAS mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CMAS expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

LUAD, CCRCC, and UCEC are the cancer types where CMAS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.509	0.901	.001	39	view →
CCRCC	DFS	Median	All	0.612	0.853	<.001	28	view →
UCEC	OS	Quartile	III,IV	0.329	1.000	.036	12	view →
GBM	DFS	Tertile	All	0.466	0.238	.007	8	view →
LSCC	OS	Median	II,III,IV	0.810	1.000	.035	1	view →
PDAC	OS	Tertile	III,IV	1.000	0.621	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CMAS–LUAD (OS)

Open the LUAD breakdown →